European training network for development of personalized anti-infective medical devices combining printing technologies and antimicrobial functionality


The mission of PRINT-AID is to provide multi-disciplinary training in microbial biofilms, 3D-printing technologies and in vivo infection models. PRINT-AID consortium will offer a training programme for early-stage researchers to exploit the power of emerging technologies in order to explore innovative routes to counteract biofilm caused infections in medical devices.

At the moment, the opportunities for young researchers to receive a structured, inter-sectoral and up-to-date education on personalized medicine and medical devices and related data standardization and integration in Europe are marginal. PRINT-AID will be the first European Training Network set up for this purpose.

The project brings together the leaders of their own areas in the personalised medicine and medical devices sector. The students have an opportunity to work both in the collaborating companies and in academia.
The project also offers great opportunities for young researchers to move from academy into industry and vice versa, and get exposed to both environments.

By using 3D printing, PRINT-AID project aims at preventing infections caused by microbial biofilms in medical devices

The European Center for Disease Prevention and Control (ECDC) states that more than four million EU patients get healthcare-associated infections every year, resulting in 37,000 deaths annually. An overwhelming proportion of those infections are caused by microbial biofilms in medical devices.

 IMG 1890Our aim is to proof the value of developing a new generation of safer 3D-printed personalised medical devices with antimicrobial functionalities. We are going to use investigational drugs which inhibit bacterial colonisation or kill bacteria. These compounds will be incorporated in the medical device structure itself during the 3D printing process and they are expected to be released from there during a long period of time. By using 3D-printing, we can also customise the devices to fit the needs of the patients. The chances of this project to provide a safer alternative for pharma devices are really significant.

In the project, state-of-the-art printing technologies will be combined with new in vitro and in vivo biofilm models as well as new tools for data integration and standardisation.

For finding out solutions for the problem, the PRINT-AID project has been granted Horizon2020 funding of 2.3 million euros for four years.